Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 EC 2115

Next Previous
X
Search
Drug Profile

Gallium-68 EC 2115

Alternative Names: 68Ga-EC2115; EC2115

Latest Information Update: 28 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue University
  • Developer Endocyte; Vanderbilt University Medical Center
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Sep 2021 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(Diagnosis, In the elderly, In adults) in USA (IV, Injection)
  • 13 Apr 2020 Endocyte and Vanderbilt University Medical Center suspend a phase I trial in Chronic obstructive pulmonary disease (Diagnosis, In adults, In the elderly) in USA (IV) owing to COVID-2019 pandemic (NCT03494114)
  • 21 Dec 2018 Endocyte has been acquired by Novartis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top